Liposomes: a promising carrier for respiratory syncytial virus therapeutics

Sameer Joshi, Swapnil Bawage, Pooja Tiwari, Daniel Kirby, Yvonne Perrie, Vida Dennis, Shree R Singh

Research output: Contribution to journalReview article

Abstract

Introduction: Human respiratory syncytial virus (RSV) is a common respiratory virus that causes severe lower respiratory tract infection in infants, children and aged adults. Currently, there is no active prophylaxis present in the market for RSV infection; however, there are over a dozen compounds being tested in the laboratory as well as clinical trials. To increase the efficiency and safety of these therapeutics, there is a need for delivery vehicles. Areas covered: Liposomes can be used for delivering anti-RSV agents with the advantage of modulating and eliciting the desired adjuvant effect by the different combination of lipids. This review discusses the promising application of liposome for anti-RSV therapeutics. Expert opinion: Liposomes are attracting attention for delivery of pulmonary therapeutics, since they offer compatibility for delivering drugs, vaccines and other therapeutic molecules. Variation in liposome size and composition gives flexibility for the amount and number of deliverables, whilst targeted delivery with the capability for immunomodulation makes liposomes a promising candidate for RSV therapeutic applications.

Original languageEnglish
Pages (from-to)969-980
Number of pages12
JournalExpert Opinion on Drug Delivery
Volume16
Issue number9
DOIs
Publication statusPublished - 7 Aug 2019

Fingerprint

Respiratory Syncytial Viruses
Liposomes
Human respiratory syncytial virus
Therapeutics
Respiratory Syncytial Virus Infections
Immunomodulation
Expert Testimony
Respiratory Tract Infections
Vaccines
Clinical Trials
Viruses
Lipids
Safety
Lung
Pharmaceutical Preparations

Bibliographical note

This is an Accepted Manuscript of an article published by Taylor & Francis Group in
Expert Opinion on Drug Delivery on 7 Aug 2019, available online at: http://www.tandfonline.com/10.1080/17425247.2019.1652268

Keywords

  • RSV
  • drugs
  • lipids
  • liposomes
  • peptides
  • small molecules

Cite this

Joshi, Sameer ; Bawage, Swapnil ; Tiwari, Pooja ; Kirby, Daniel ; Perrie, Yvonne ; Dennis, Vida ; Singh, Shree R. / Liposomes : a promising carrier for respiratory syncytial virus therapeutics. In: Expert Opinion on Drug Delivery. 2019 ; Vol. 16, No. 9. pp. 969-980.
@article{cd7d91f2269e4818b725e102480764fc,
title = "Liposomes: a promising carrier for respiratory syncytial virus therapeutics",
abstract = "Introduction: Human respiratory syncytial virus (RSV) is a common respiratory virus that causes severe lower respiratory tract infection in infants, children and aged adults. Currently, there is no active prophylaxis present in the market for RSV infection; however, there are over a dozen compounds being tested in the laboratory as well as clinical trials. To increase the efficiency and safety of these therapeutics, there is a need for delivery vehicles. Areas covered: Liposomes can be used for delivering anti-RSV agents with the advantage of modulating and eliciting the desired adjuvant effect by the different combination of lipids. This review discusses the promising application of liposome for anti-RSV therapeutics. Expert opinion: Liposomes are attracting attention for delivery of pulmonary therapeutics, since they offer compatibility for delivering drugs, vaccines and other therapeutic molecules. Variation in liposome size and composition gives flexibility for the amount and number of deliverables, whilst targeted delivery with the capability for immunomodulation makes liposomes a promising candidate for RSV therapeutic applications.",
keywords = "RSV, drugs, lipids, liposomes, peptides, small molecules",
author = "Sameer Joshi and Swapnil Bawage and Pooja Tiwari and Daniel Kirby and Yvonne Perrie and Vida Dennis and Singh, {Shree R}",
note = "This is an Accepted Manuscript of an article published by Taylor & Francis Group in Expert Opinion on Drug Delivery on 7 Aug 2019, available online at: http://www.tandfonline.com/10.1080/17425247.2019.1652268",
year = "2019",
month = "8",
day = "7",
doi = "10.1080/17425247.2019.1652268",
language = "English",
volume = "16",
pages = "969--980",
journal = "Expert Opinion on Drug Delivery",
issn = "1742-5247",
publisher = "Informa Healthcare",
number = "9",

}

Liposomes : a promising carrier for respiratory syncytial virus therapeutics. / Joshi, Sameer; Bawage, Swapnil; Tiwari, Pooja; Kirby, Daniel; Perrie, Yvonne; Dennis, Vida; Singh, Shree R.

In: Expert Opinion on Drug Delivery, Vol. 16, No. 9, 07.08.2019, p. 969-980.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Liposomes

T2 - a promising carrier for respiratory syncytial virus therapeutics

AU - Joshi, Sameer

AU - Bawage, Swapnil

AU - Tiwari, Pooja

AU - Kirby, Daniel

AU - Perrie, Yvonne

AU - Dennis, Vida

AU - Singh, Shree R

N1 - This is an Accepted Manuscript of an article published by Taylor & Francis Group in Expert Opinion on Drug Delivery on 7 Aug 2019, available online at: http://www.tandfonline.com/10.1080/17425247.2019.1652268

PY - 2019/8/7

Y1 - 2019/8/7

N2 - Introduction: Human respiratory syncytial virus (RSV) is a common respiratory virus that causes severe lower respiratory tract infection in infants, children and aged adults. Currently, there is no active prophylaxis present in the market for RSV infection; however, there are over a dozen compounds being tested in the laboratory as well as clinical trials. To increase the efficiency and safety of these therapeutics, there is a need for delivery vehicles. Areas covered: Liposomes can be used for delivering anti-RSV agents with the advantage of modulating and eliciting the desired adjuvant effect by the different combination of lipids. This review discusses the promising application of liposome for anti-RSV therapeutics. Expert opinion: Liposomes are attracting attention for delivery of pulmonary therapeutics, since they offer compatibility for delivering drugs, vaccines and other therapeutic molecules. Variation in liposome size and composition gives flexibility for the amount and number of deliverables, whilst targeted delivery with the capability for immunomodulation makes liposomes a promising candidate for RSV therapeutic applications.

AB - Introduction: Human respiratory syncytial virus (RSV) is a common respiratory virus that causes severe lower respiratory tract infection in infants, children and aged adults. Currently, there is no active prophylaxis present in the market for RSV infection; however, there are over a dozen compounds being tested in the laboratory as well as clinical trials. To increase the efficiency and safety of these therapeutics, there is a need for delivery vehicles. Areas covered: Liposomes can be used for delivering anti-RSV agents with the advantage of modulating and eliciting the desired adjuvant effect by the different combination of lipids. This review discusses the promising application of liposome for anti-RSV therapeutics. Expert opinion: Liposomes are attracting attention for delivery of pulmonary therapeutics, since they offer compatibility for delivering drugs, vaccines and other therapeutic molecules. Variation in liposome size and composition gives flexibility for the amount and number of deliverables, whilst targeted delivery with the capability for immunomodulation makes liposomes a promising candidate for RSV therapeutic applications.

KW - RSV

KW - drugs

KW - lipids

KW - liposomes

KW - peptides

KW - small molecules

UR - https://www.tandfonline.com/doi/abs/10.1080/17425247.2019.1652268?journalCode=iedd20

UR - http://www.scopus.com/inward/record.url?scp=85070510236&partnerID=8YFLogxK

U2 - 10.1080/17425247.2019.1652268

DO - 10.1080/17425247.2019.1652268

M3 - Review article

C2 - 31382795

VL - 16

SP - 969

EP - 980

JO - Expert Opinion on Drug Delivery

JF - Expert Opinion on Drug Delivery

SN - 1742-5247

IS - 9

ER -